

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1-55. (canceled)

56. (currently amended) A method for inhibiting angiogenesis in a ~~mammal~~ tumor comprising administering to the ~~mammal~~ tumor an effective amount of an antibody or antigen binding fragment thereof that specifically binds and neutralizes a polypeptide comprising an amino acid sequence of SEQ ID NO:76.

57-68. (canceled)

69. (previously presented) The method of claim 56, wherein the polypeptide is encoded by a polynucleotide comprising a nucleic acid sequence of SEQ ID NO:75.

70. (previously presented) The method of claim 56, wherein said antibody is a polyclonal antibody, a monoclonal antibody, an antibody fragment, a human antibody, a humanized antibody, a chimeric antibody, a bispecific antibody or a heteroconjugate antibody.

71. (previously presented) The method of claim 70, wherein said antibody is an antagonist or a neutralizing antibody.

72. (previously presented) The method of claim 56, wherein the antibody has polypepitopic specificity.

73. (previously presented) The method of claim 56, wherein the antibody is a human antibody, a chimeric antibody, or a humanized antibody.

74. (previously presented) The method of claim 56, wherein the antibody is an antibody fragment.

75. (previously presented) The method of claim 74, wherein the antibody fragment comprises a Fab fragment, a Fab' fragment, a F(ab')₂ fragment, or a Fv fragment.

76. (previously presented) The method of claim 56, wherein the antibody is a heteroconjugate antibody.

77. (previously presented) The method of claim 73, wherein the antibody is a humanized antibody.

78. (new) The method of claim 56, wherein the tumor is a breast carcinoma, renal cell carcinoma, squamous cell carcinoma, colon carcinoma, and prostate carcinoma.

79. (new) The method of claim 78, wherein the tumor is a breast carcinoma.

80. (new) A method of inhibiting PMA-induced angiogenesis of endothelial cells, comprising administering to said endothelial cells an antibody or antigen binding fragment thereof that specifically binds and neutralizes a polypeptide comprising an amino acid sequence of SEQ ID NO:76.